Projected Number of People With Parkinson Disease in the Most Populous Nations, 2005 Through 2030

Calabrese, Vincent P.; Dorsey, E .R.; Constantinescu, R .; Thompson, J. P.; Biglan, K .M.; Holloway, Robin; Kieburtz, K .; Marshall, Frederick J.; Ravina, Bernard; Schifitto, G .; Siderowf, A .; Tanner, C .M.

doi:10.1212/01.wnl.0000271777.50910.73

Cited by 60 publications

(39 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting more than 4 million people worldwide (Calabrese et al, 2007). Clinical manifestations of PD include bradykinesia, postural instability, resting tremor, and rigidity as well as increased susceptibility to memory impairment and behavioral alterations (Savitt et al, 2006).…”

Section: Introductionmentioning

confidence: 99%

Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes

Scott

Dawson

2017

Experimental Neurology

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a neurodegenerative movement disorder characterized by the progressive loss of dopaminergic (DA) neurons. Most PD cases are sporadic; however, rare familial forms have been identified. Autosomal recessive PD (ARPD) results from mutations in Parkin, PINK1, DJ-1, and ATP13A2, while rare, atypical juvenile ARPD result from mutations in FBXO7, DNAJC6, SYNJ1, and PLA2G6. Studying these genes and their function has revealed mitochondrial quality control, protein degradation processes, and oxidative stress responses as common pathways underlying PD pathogenesis. Understanding how aberrancy in these common processes leads to neurodegeneration has provided the field with numerous targets that may be therapeutically relevant to the development of disease-modifying treatments.

show abstract

Section: Introductionmentioning

confidence: 99%

Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes

Scott

Dawson

2017

Experimental Neurology

View full text Add to dashboard Cite

show abstract

“…One of those disorders is Parkinson’s disease (PD) (Calabrese, 2007). According to the World Health Organization, more than 5.2 million people were affected by PD in 2004 (), and this number is expected to increase to 40 million by the year 2020 (Morris, 2000).…”

Section: Introductionmentioning

confidence: 99%

Using a Smart Phone as a Standalone Platform for Detection and Monitoring of Pathological Tremors

Daneault¹,

Carignan²,

Codère³

et al. 2013

Front. Hum. Neurosci.

View full text Add to dashboard Cite

Introduction: Smart phones are becoming ubiquitous and their computing capabilities are ever increasing. Consequently, more attention is geared toward their potential use in research and medical settings. For instance, their built-in hardware can provide quantitative data for different movements. Therefore, the goal of the current study was to evaluate the capabilities of a standalone smart phone platform to characterize tremor. Results: Algorithms for tremor recording and online analysis can be implemented within a smart phone. The smart phone provides reliable time- and frequency-domain tremor characteristics. The smart phone can also provide medically relevant tremor assessments. Discussion: Smart phones have the potential to provide researchers and clinicians with quantitative short- and long-term tremor assessments that are currently not easily available. Methods: A smart phone application for tremor quantification and online analysis was developed. Then, smart phone results were compared to those obtained simultaneously with a laboratory accelerometer. Finally, results from the smart phone were compared to clinical tremor assessments.

show abstract

“…Since population worldwide is aging gradually, it is predicted by Dorsey et al . that the population of patients affected by PD will double in 20305. Apart from the high prevalence rate among elder males, PD is also characterized with a high mortality.…”

mentioning

confidence: 99%

Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis

Zhuo

Zhu

Jiang³

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a long term disorder affects the central nervous system and we aim to determine the relative efficacy of the current available drugs used in PD. Firstly, we performed a systematic review in current literature and eligible studies were retrieved from online databases, relevant data were extracted. Efficacy of these medications was assessed by different Unified Parkinson’s Disease Rating Scales (UPDRS). Mean difference (MD) and odds ratio (OR) were produced by pairwise or network meta-analysis (NMA). Finally, we performed a cluster analysis for the included medications with respect to their surface under the cumulative ranking curve (SUCRA). Pairwise meta-analysis suggests that selegiline had a higher ranking in UPDRS II, UPDRS III and UPDRS total than bromocriptine and levodopa. Selegiline was more tolerable than bromocriptine (OR = 0.62, CI: 0.39 to 0.98) and pramipexole was less tolerable than levodopa (OR = 1.43, CI = 1.00 to 2.04). Results of NMA indicate that patients with levodopa, pramipexole, ropinirole and selegiline exhibited a significantly improved UPDRS III than those with lazabemide. To sum up, levodopa, selegiline, ropinirole and rotigotine were recommended for PD patients as they appeared relatively high efficacy and tolerability.

show abstract

Projected Number of People With Parkinson Disease in the Most Populous Nations, 2005 Through 2030

Cited by 60 publications

References 4 publications

Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes

Trumping neurodegeneration: Targeting common pathways regulated by autosomal recessive Parkinson's disease genes

Using a Smart Phone as a Standalone Platform for Detection and Monitoring of Pathological Tremors

Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis

Contact Info

Product

Resources

About